TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 6119939
Drug: epidural injection
Normalized name: Sufentanil Citrate 50 ug in 1 mL EPIDURAL INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: epidural injection of morphine after neuroleptoanaesthesia
Study: 17968815
Drug: Silymarin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (280 mg administered 10 hours and 1.5 hours prior to nifedipine)
Study: 17968815
Drug: Nifedipine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (10 mg) alone
Study: 21865319
Drug: Silymarin (280
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin (280 mg)
Study: 17968815
Drug: Nifedipine and
Normalized name: nifedipine and diuretics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine and silymarin co-administration
Study: 15156430
Drug: Once-daily HAART
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily HAART
Study: 15156430
Drug: Twice-daily HAART
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily HAART
Study: 10553804
Drug: SS-cream 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.05 g
Study: 10553804
Drug: SS-cream 0.10
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.10 g
Study: 10553804
Drug: SS-cream 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.15 g
Study: 10688090
Drug: SS-cream 0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: SS-cream 0.20 g
Study: 2119153
Drug: Alfentanil (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfentanil (50 micrograms/kg IV bolus followed by infusion at 1 micrograms.kg‐1.min‐1)
Study: 710268
Drug: Traditional supportive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional supportive therapy (TST)
Study: 24089054
Drug: Sodium benzoate
Normalized name: Sodium Benzoate
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium benzoate (1 g/d)
Study: 19786674
Drug: Decision aid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Decision aid for diabetes medication choice
Study: 15246627
Drug: BEC2 anti-idiotypic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BEC2 anti-idiotypic monoclonal antibody vaccine (2.5 microg - 10 mg)
Study: 15246627
Drug: BEC2 anti-idiotypic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BEC2 anti-idiotypic monoclonal antibody vaccine (lower three dose levels)
Study: 15246627
Drug: BEC2 anti-idiotypic
Normalized name: anti-CD11a
DrugBank: Efalizumab (DB00095)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: BEC2 anti-idiotypic monoclonal antibody vaccine (high doses)
Study: 12218721
Drug: Soy isoflavone
Normalized name: soy isoflavone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy isoflavone extract (70 mg genistin and daidzin per day)
Study: 7619676
Drug: 5-hydroxy-L-tryptophan (5-HTP)
Normalized name: 5-hydroxy-L-tryptophan
DrugBank: Oxitriptan (DB02959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-hydroxy-L-tryptophan (5-HTP)
Study: 362297
Drug: cyclophosphamide (additional
Approvals — FDA: no, EMA: no, PMDA: no
Description: cyclophosphamide (additional treatment during second interval)
Study: 30368163
Drug: MSI-195 800
Normalized name: morphine sulfate Oral Solution [MSIR]
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSI-195 800 mg added to ongoing ADT
Study: 23135172
Drug: Planned Treatment
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Planned Treatment Interruption (PTI)
Study: 16136947
Drug: Composite Xin
Normalized name: methyl salicylate
DrugBank: Methyl salicylate (DB09543)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Composite Xin Mai Tong (XMT) capsules
Study: 12189365
Drug: Citalopram (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (20 mg to 40 mg once daily)
Study: 8750400
Drug: Ondansetron 8
Normalized name: ondansetron 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron 8 mg twice daily for 3 days
Study: 6110654
Drug: Lithium carbonate
Normalized name: Lithium Carbonate
DrugBank: Lithium carbonate (DB14509)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lithium carbonate added to neuroleptic treatment
Study: 28978543
Drug: Cream cheese
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cream cheese
Study: 27852706
Drug: AbobotulinumtoxinA (BoNT‐A)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (BoNT‐A) injection guided by electrostimulation
Study: 27852706
Drug: AbobotulinumtoxinA (BoNT‐A)
Normalized name: abobotulinumtoxinA
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Description: AbobotulinumtoxinA (BoNT‐A) injection guided by ultrasound
Study: 24468886
Drug: GCPGC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCPGC at 100 μg/kg
Study: 24468886
Drug: GCPGC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCPGC at 30-100 μg/kg
Study: 24468886
Drug: GCPGC at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: GCPGC at 300 μg/kg
Study: 24468886
Drug: Pegfilgrastim at
Normalized name: Pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pegfilgrastim at 100 μg/kg
Study: 22081256
Drug: Clopidogrel tapering
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel tapering (75 mg every other day for 4 weeks)
Study: 18065578
Drug: Fish-oil capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish-oil capsules - 1-2 capsules per day
Study: 16617852
Drug: Group 1
Normalized name: Chlamydophila psittaci biogroup 1 Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group 1 (blood sampling for hormone analysis)
Study: 8688981
Drug: Cimetidine (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine (400 mg t.i.d.)
Study: 6496286
Drug: Verapamil (453
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (453 ± 75 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Study: 6496286
Drug: Nifedipine (71
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (71 ± 14 mg per day) + Isosorbide dinitrate (117 ± 63 mg per day)
Study: 6496286
Drug: Isosorbide dinitrate
Normalized name: Isosorbide Dinitrate
DrugBank: Isosorbide dinitrate (DB00883)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Isosorbide dinitrate (117 ± 63 mg per day) alone
Study: 29902299
Drug: Dual HER2-targeted
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dual HER2-targeted therapy (lapatinib and trastuzumab)
Study: 27357281
Drug: Cerebrospinal fluid
Normalized name: amniotic fluid (bovine)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cerebrospinal fluid (CSF) neopterin levels in delirium patients (median 29.6 nmol/mL)
Study: 27357281
Drug: Serum neopterin
Normalized name: Neopterin
DrugBank: Neopterin (DB15050)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum neopterin levels in delirium patients (median 37.0 nmol/mL)
Study: 22999380
Drug: Community reinforcement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community reinforcement approach (CRA) treatment
Study: 20459475
Drug: Green tea
Normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Green tea extract (GTE) - 572.8 mg tea catechins (TC) daily
Study: 20459475
Drug: Placebo (PLA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA) - 0 mg tea catechins (TC) daily
Study: 16820802
Drug: Standard sodium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard sodium fluoride dentifrice (treatment period 1)
Study: 16820802
Drug: Standard sodium
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard sodium fluoride dentifrice (treatment period 2)
Study: 16820802
Drug: Antimicrobial stannous
Normalized name: Stannous chloride
DrugBank: Stannous chloride (DB11056)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial stannous fluoride/sodium hexametaphosphate dentifrice (treatment period 3)
Study: 10763941
Drug: Rabeprazole 20
Normalized name: RABEprazole 20 mg oral delayed release tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rabeprazole 20 mg q.a.m.
Study: 3119287
Drug: Six capsules
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six capsules (Norplant)
Study: 30305280
Drug: Eltrombopag (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag (200 mg/d, max 300 mg/d for East Asians) plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Study: 30305280
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus azacitidine (75 mg/m2 subcutaneously once daily for 7 days every 28 days)
Study: 26528941
Drug: Atropine sulfate
Normalized name: Atropine Sulfate
DrugBank: Atropine (DB00572)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Atropine sulfate (0.02 mg/kg)
Study: 25180479
Drug: Hypoenergetic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoenergetic diet rich in ALA (3.4 g/d)
Study: 25180479
Drug: Hypoenergetic diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypoenergetic diet low in ALA (0.9 g/d, control)
Study: 16037757
Drug: Topical vaginal
Normalized name: emollients, topical vaginal gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical vaginal estrogen therapy (ET group)
Study: 8049820
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D (1,000 IU/d), Calcium (1 g/d), EHDP (7.5 mg/kg body weight)
Study: 2838923
Drug: Kabi 2165
Normalized name: immunoglobulin G, human Injectable Solution [Kabiglobulin]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kabi 2165 (2,500 anti-Xa units once daily)
Study: 2838923
Drug: Calcium heparin
Normalized name: HEPARIN CALCIUM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium heparin (5,000 IU twice daily)
Study: 28472415
Drug: Acupressure treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupressure treatment (15 min, 4 times a week for 12 weeks)
Study: 15600379
Drug: SSRIs (fluoxetine,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (fluoxetine, paroxetine, sertraline, citalopram)
Study: 11327200
Drug: tolterodine ER
Normalized name: tolterodine Extended Release Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine ER 4mg once daily
Study: 11327200
Drug: tolterodine IR
Approvals — FDA: no, EMA: no, PMDA: no
Description: tolterodine IR 2mg twice daily
Study: 9387134
Drug: Oral protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral protein load (2 g/kg of protein as beefsteak)
Study: 9387134
Drug: Group A
Normalized name: Blood group A IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A (GFR 112 +/- 3 ml/min x 1.73 m2)
Study: 9387134
Drug: Group B
Normalized name: Blood group B IgM
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B (GFR 68 +/- 3.2 ml/min x 1.73 m2)
Study: 9387134
Drug: Group C
Normalized name: STREPTOCOCCUS ANTIGEN (GROUP C)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group C (GFR 40.7 +/- 3.3 ml/min x 1.73 m2)
Study: 7968283
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg of ferric ammonium citrate
Study: 10394873
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg of ferric ammonium citrate
Study: 7968283
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of parasympathetic blockers
Study: 2737270
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg prednisolone
Study: 21174921
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg prednisolone
Study: 24298767
Drug: Electroacupuncture +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture + Acupoint Injection (EA + AI)
Study: 22649136
Drug: Low-dose involved-field
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose involved-field radiation therapy (IFRT)
Study: 2832549
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy (control)
Study: 3280128
Drug: Haloperidol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (2.5 mg)
Study: 11263519
Drug: Full-dose regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full-dose regimen of isoniazid, rifampicin, pyrazinamide and ethambutol (Group II, n = 25)
Study: 8027221
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg YM175
Study: 8027221
Drug: Lower doses
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower doses of YM175
Study: 30986790
Drug: CYD‐TDV (Dengvaxia)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CYD‐TDV (Dengvaxia) booster dose
Study: 28494809
Drug: Physical exercise
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical exercise and dietary therapy (PED-t) for 16 weeks
Study: 28494809
Drug: Cognitive behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behavioral therapy (CBT) for 16 weeks
Study: 24399727
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose metformin (3 g daily in three divided doses)
Study: 17679042
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 40 mg
Study: 16956341
Drug: Inosiplex, 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inosiplex, 50 mg/kg daily per os for 12 weeks
Study: 12648031
Drug: Fluvastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin (20-40 mg/day, or 40 mg twice daily)
Study: 12648031
Drug: Lovastatin (20-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin (20-40 mg/day, or 40 mg twice daily)
Study: 12648031
Drug: Pravastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin (10-40 mg/day)
Study: 8590530
Drug: Simvastatin (10-40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10-40 mg/day)
Study: 10638663
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 50 mg/kg body weight in 5% dextrose
Study: 10638663
Drug: N-acetylcysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: N-acetylcysteine (NAC) 50 mg/kg + rutin 5 mg/kg in 5% dextrose
Study: 9402073
Drug: HIV vaccine
Normalized name: AAV-2 HIV Vaccine
DrugBank: TGAAC09 (DB06363)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIV vaccine intervention
Study: 3965439
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of haloperidol
Study: 17888803
Drug: CALM intervention
Normalized name: Eucerin Calming Itch Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: CALM intervention (education and behavioral activation delivered by anxiety clinical specialists, with options for cognitive-behavioral therapy, antianxiety medications, or both)
Study: 9660534
Drug: Granisetron plus
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron plus methylprednisolone (250 mg i.v. twice daily)
Study: 9660534
Drug: Granisetron alone
Normalized name: Granisetron
DrugBank: Granisetron (DB00889)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Granisetron alone (3 mg i.v. over 30 s)
Study: 8704424
Drug: Zhong Feng
Normalized name: Feng Mi
DrugBank: Honey (DB14242)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zhong Feng I oral liquor (acute stage), Zhong Feng II oral liquor (convalescent stage) and Western medicine
Study: 2515723
Drug: Deprenyl 10
Normalized name: (11C)L-deprenyl-D2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deprenyl 10 mg per day
Study: 24791510
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy of small needle knife and Daqinjiu Tang
Study: 21330911
Drug: ALVAC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALVAC with Remune and ALVAC alone (combined vaccine groups)
Study: 30353603
Drug: Musical training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Musical training (weekly 45-min lessons for 52 weeks)
Study: 21225098
Drug: Oral dabigatran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral dabigatran 220 mg once-daily
Study: 17764540
Drug: Subcutaneous enoxaparin
Normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous enoxaparin 40 mg once-daily
Study: 17356145
Drug: High-energy extracorporeal
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-energy extracorporeal shock-wave therapy
Study: 17356145
Drug: Low-energy extracorporeal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-energy extracorporeal shock-wave therapy
Study: 15359161
Drug: Wide diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wide diameter implants (5.0 and 6.0 mm)
Study: 15359161
Drug: Standard diameter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard diameter implants (3.75 and 4.0 mm)
Study: 11123735
Drug: Diazepam, 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam, 0.4 mg x kg(‐1)
Study: 7989502
Drug: Onapristone 5
Normalized name: Onapristone
DrugBank: Onapristone (DB12637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onapristone 5 mg/day
Study: 7989502
Drug: Onapristone 15
Normalized name: Onapristone
DrugBank: Onapristone (DB12637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onapristone 15 mg/day
Study: 7989502
Drug: Onapristone 50
Normalized name: Onapristone
DrugBank: Onapristone (DB12637)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Onapristone 50 mg/day
Study: 7989502
Drug: Post-treatment (after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-treatment (after discontinuation of onapristone)
Study: 7989502
Drug: Luteal phase
Normalized name: Nuphar lutea leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Luteal phase post-treatment
Study: 5579489
Drug: Gradual withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gradual withdrawal of anticholinergic drugs over four weeks
Study: 5579489
Drug: Abrupt withdrawal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Abrupt withdrawal of anticholinergic drugs
Study: 5579489
Drug: Stable levodopa
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Stable levodopa therapy with anticholinergic drugs
Study: 28264826
Drug: Computer-determined dosage
Normalized name: osage orange pollen extract
DrugBank: Maclura pomifera pollen (DB10988)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-determined dosage of insulin (CDD) using the STAR-GRYPHON model
Study: 28264826
Drug: Bedside titration:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedside titration: insulin dose determined by medical staff
Study: 28264826
Drug: Standard care:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care: insulin dose and frequency of blood glucose testing determined by medical staff
Study: 23206182
Drug: Rivastigmine monotherapy
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine monotherapy
Study: 23206182
Drug: Rivastigmine combination
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine combination therapy
Study: 23206182
Drug: Memantine in
Normalized name: memantine Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memantine in combination therapy
Study: 8569424
Drug: Ranitidine 300
Normalized name: ranitidine 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine 300 mg orally each evening for 1 week
Study: 1910730
Drug: Perioperative and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative and postoperative steroid use
Study: 369651
Drug: Dummy tablets
Normalized name: cholecalciferol / tricalcium phosphate Chewable Tablet [Caltrate Gummy Bites]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dummy tablets (control)
Study: 31519527
Drug: Psychosocial variables
Normalized name: Ferric carbonate, ferric hydroxide, ferrous hydroxide (variable mixture)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychosocial variables (including religiosity, knowledge regarding blood donation process, overall quality of life, blood donation of peers, sociodemographic variables, fear of blood, injections, and fainting)
Study: 23319135
Drug: Clinofibrate (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinofibrate (all doses)
Study: 21881066
Drug: Protease inhibitor
Normalized name: Protease inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protease inhibitor (PI)-based HAART
Study: 21881066
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitor-based HAART (without PI)
Study: 29311704
Drug: Ramipril 5
Normalized name: ramipril 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramipril 5 mg/day
Study: 17446306
Drug: Pregabalin (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (200 mg tid for 3 weeks)
Study: 11104592
Drug: Early postoperative
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early postoperative gastric supply of nutrients (Osmolite, Ross; first 3 hours 30 ml/h and second 3 hours 50 ml/h; total 240 ml after 6 hours)
Study: 11104592
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (crystalloid solutions only)
Study: 8142781
Drug: EMLA cream
Normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Prilocaine (DB00750)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EMLA cream (eutectic mixture of local anesthetics) applied for 3 minutes
Study: 2873397
Drug: Oral B
Normalized name: bran ORAL BOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral B subunit killed whole‐cell (BS‐WC) vaccine
Study: 2873397
Drug: Killed whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed whole‐cell (WC) vaccine
Study: 15670563
Drug: Oral methionine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral methionine administration
Study: 8947993
Drug: Bromfenac 5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bromfenac 5, 10, 25, 50, or 100 mg